DescriptionMarina Biotech, Inc., formerly known as MDRNA, Inc., is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Company's pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs in hepatocellular carcinoma and bladder cancer. Marina's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Marina Biotech, Inc. is headquartered in Bothell, Washington.
Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.
Stock Reports +
Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 0.4000 +12.50% increase |
| 0.7000 -35.71% decrease |
| -0.1000 (-18.18%) decrease |
|3-Month|| 0.4000 +12.50% increase |
| 0.8000 -43.75% decrease |
| -0.2100 (-31.82%) decrease |
|52-Week|| 0.4000 +12.50% increase |
| 2.4000 -81.25% decrease |
| -1.9500 (-81.25%) decrease |